Blog

Amol Akhade: Intraperitoneal chemotherapy may hold promise for gastric cancer

Amol Akhade/LinkedIn

Jan 23, 2025, 14:32

Amol Akhade: Intraperitoneal chemotherapy may hold promise for gastric cancer

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared the following on X:

“Intraperitoneal paclitaxel added to IV paclitaxel plus S1 in advanced gastric cancer with peritoneal metastases in first-line improves median OS by close to 5.5 months (19.4 months vs. 13.9 months) and 2-year OS by 17% (37.2% vs. 20.3%).

Data from Phase 3 RCT – Dragon-01 trial from China. Surprisingly less toxicity was seen in the IP arm. This looks interesting and may increase interest in intraperitoneal chemotherapy in gastric cancer. Will it hold true in the era of IO?

Looking forward to presention in GI25 ”

Amol Akhade cancer Cancer research Cancer Treatment Advances chemotherapy innovations China Dragon-01 trial gastric cancer Healthcare Innovation intraperitoneal chemotherapy OncoDaily Oncology Phase 3 Trial survival outcomes

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology